Globus Medical (NYSE:GMED) Stock Rating Lowered by Wall Street Zen

Key Points

• Globus Medical was downgraded by Wall Street Zen from strong-buy to buy, though the broader analyst picture remains positive with a consensus rating of Moderate Buy and an average price target of $106.36.
• The company posted a strong quarter, beating expectations with $1.12 EPS versus $0.92 expected and $759.9 million in revenue versus $740.4 million expected, while sales rose 27% year over year.
• Management raised FY2026 EPS guidance to $4.70-$4.80, but the stock still sold off as investors appeared to take profits despite the better-than-expected results and upbeat analyst target revisions.

Globus Medical (NYSE:GMED - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a report issued on Saturday.

A number of other research analysts have also commented on GMED. Royal Bank Of Canada increased their price objective on Globus Medical from $115.00 to $120.00 and gave the company an "outperform" rating in a research report on Friday. Weiss Ratings reiterated a "hold (c+)" rating on shares of Globus Medical in a research report on Wednesday, April 15th. Needham & Company LLC increased their price objective on Globus Medical from $114.00 to $117.00 and gave the company a "buy" rating in a research report on Friday. Truist Financial set a $115.00 price objective on Globus Medical in a research report on Wednesday, February 25th. Finally, Zacks Research upgraded Globus Medical from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $106.36.

Globus Medical Stock Performance

Shares of GMED opened at $77.81 on Friday. The firm has a market capitalization of $10.52 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 1.99 and a beta of 1.00. The business's fifty day moving average price is $89.86 and its two-hundred day moving average price is $86.65. Globus Medical has a 52 week low of $51.79 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a return on equity of 13.69% and a net margin of 18.92%.The business's quarterly revenue was up 27.0% compared to the same quarter last year. During the same period last year, the company earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts forecast that Globus Medical will post 4.46 EPS for the current year.

Insider Activity

In other news, EVP Kelly Huller sold 20,000 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 18.38% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GMED. Invesco Ltd. boosted its position in shares of Globus Medical by 1,235.2% in the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company's stock worth $339,322,000 after purchasing an additional 3,595,339 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Globus Medical by 15,317.1% in the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company's stock worth $294,519,000 after purchasing an additional 3,351,380 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Globus Medical by 1,303.9% in the 3rd quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company's stock worth $117,700,000 after purchasing an additional 1,908,795 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new position in shares of Globus Medical in the 4th quarter worth $90,411,000. Finally, Norges Bank bought a new position in shares of Globus Medical in the 4th quarter worth $89,922,000. 95.16% of the stock is currently owned by institutional investors.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Globus Medical beat Q1 expectations on both earnings and revenue, reporting $1.12 EPS versus $0.92 expected and $759.9 million in sales versus $740.4 million expected; revenue rose 27% year over year and margins improved. Article Title
• Positive Sentiment: The company also raised FY2026 EPS guidance to $4.70-$4.80, above consensus, signaling management confidence in continued growth. Article Title
• Positive Sentiment: Royal Bank of Canada lifted its price target on GMED to $120 from $115 and kept an outperform rating, while Needham raised its target to $117 from $114 and reiterated a buy rating, reflecting bullish analyst sentiment. Article Title
• Neutral Sentiment: Investors are also digesting the company’s Q1 earnings call transcript and related post-earnings coverage, which primarily reinforce the strong results rather than adding new catalysts. Article Title
• Negative Sentiment: Despite the beat and higher guidance, the stock has sold off as traders appear to be taking profits and focusing on expectations that were already elevated going into the report. Article Title

About Globus Medical

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.